Glutathione S-transferases (GSTs) are phase II detoxification enzymes involved in the metabolism of carcinogens and anticancer drugs, known also to interact with kinase complexes during oxidative or chemical stress-induced apoptosis. We were interested whether their polymorphic variants may account for differences in outcome of patients with acute myeloid leukemia (AML) following chemotherapy. We studied the prognostic role of polymorphisms in three GST genes (GSTP1/M1/T1) in a large patient cohort of the German Austrian Acute Myeloid Leukemia Study Group, treated according to prospective multicenter clinical trials (AML HD98A: 254 patients; AML HD98-B: 100 patients), with a median follow-up of 46 months. Looking at short-term adverse drug reactions, homozygous carriers of the GSTP1*105 Val allele had a faster neutrophil and platelet recovery (P ¼ 0.002 and 0.02, respectively) and a reduced need of red cell and platelet transfusions (P ¼ 0.01 and 0.03, respectively). Response to induction chemotherapy did not vary according to GST polymorphisms. Multivariable Cox regression models revealed a significant better relapse-free (RFS) and overall survival for the GSTP1*105 Val (P ¼ 0.003 and 0.03, respectively), whereas GSTT1 and GSTM1 genotypes had no significant impact. The favorable impact of GSTP1*105 Val on RFS seems to be restricted to the subgroup of patients exhibiting a normal karyotype.
Introduction
Xenobiotics and drugs are metabolized through enzymatic pathways, including activation into electrophilic compounds by phase I reactions, followed by biotransformation during phase II reactions, which prepare the compounds for excretion. Glutathione S-transferases (GSTs) function as phase II enzymes, that catalyzes the conjugation to glutathione resulting in detoxification of anticancer drugs and protection of the cell against peroxidative stress of lipids and nucleic acids. 1 GST isoenzymes, in particular the GSTp class have been shown to be overexpressed in tumors and in chemotherapyresistant cell lines, leading to accelerated detoxification and resistance to drugs. [2] [3] [4] [5] On the other hand, reduced enzymatic activity may not only determine inefficient detoxification and increased activity of drugs, but also prolonged damage to stem cells, leading to secondary tumorgenesis.
The interest in GST isoenzymes has further increased due to their regulatory role in the interaction with critical kinases involved in controlling stress response, apoptosis and proliferation. GSTp was the first isoenzyme shown to inhibit the c-Jun NH2-terminal kinase (JNK) complex and to play a role in the damage induced by reactive oxygen species due to oxidative or chemical stress. 6 Similar to GSTp/JNK, GSTM1 was also shown to interact with JNK, by binding to the MAP kinase ASK1. 7 In stress conditions the two GST isoenzymes allow for the release of kinases and induction of apoptosis. 8, 9 Due to their multiple functions, polymorphic variants of GST enzymes may account for interindividual differences in outcome of chemotherapy. There are several reports on the role of GSTM1 and/or GSTT1 deletions as prognosticators in acute leukemia. 10, 11 Studying 106 patients with acute myeloid leukemia (AML) treated in a single center, we have shown that individuals with a GSTM1 and/or GSTT1 deletion were at risk of relapse and of shorter overall survival (OS). This effect was limited to patients with an intermediate-risk karyotype. 12 The objectives of our study were to study the prognostic impact on outcome of the GSTP1(Ile105Val) polymorphism and of GSTM1 and/or GSTT1 deletion in a well-characterized cohort of 354 patients treated according to standard protocols of the multicenter German-Austrian AML Study Group (AMLSG, https://www.uni-ulm.de/onkologie/AMLSG/index.html).
Patients and methods

Patients and treatment
The study included 354 Caucasian patients with AML, de novo or secondary (after treatment for a primary malignancy or a myelodysplastic syndrome), as defined by the French-AmericanBritish (classification, treated in Germany according to two multicenter protocols. A total of 254 patients younger than 60 years (median age 46 years, range 16-60 years) were treated according to the AML HD98-A AMLSG multicenter trial. 13 A total of 100 elderly AML patients (median age 67 years, range 60-84 years), were treated according to the AML HD98-B AMLSG trial. [14] [15] [16] The clinical trials were approved by the institutional review boards of the participating centers. Cytogenetic subgroups were defined as: low risk: t(15;17), and inv (16) , present in 84 of 347 patients (24%); standard risk: normal karyotype, t(8;21), t(11q23), þ 8 or þ 11 within a noncomplex karyotype, in 169 of 347 patients (49%); high risk: all other aberrations, in 94 of 347 patients (27%) (16) . Informed consent was obtained from all patients according to the Declaration of Helsinki.
DNA extraction and amplification
DNA was extracted from the bone marrow or peripheral blood of patients with AML at the time of initial diagnosis. The Ile105Val polymorphism of the GSTP1 gene was analyzed using the PCR-RFLP technique as described by Harries et al. 17 DNA was amplified by PCR in a mixture containing the primers P105F (5'-ACCCCAGGGCTCTATGGGAA-3') and P105R (5'-TGA GGGCACAAGAAGCCCCT-3'), leading to a 176 bp band. The A to G polymorphism introduces a restriction site recognized by the BsmA1 restriction enzyme (New England Biolabs, Beverly, MA, USA), which results into either retention of the 176 bp product or complete digestion to 91 and 85 bp fragments, corresponding to individuals homozygous for the Ile or Val alleles, respectively. The presence of all three fragments corresponds to individuals heterozygous at codon 105.
Homozygous deletions of GSTM1 and/or GSTT1, resulting in absence of specific enzymes, were studied using a multiplex PCR technique, including the housekeeping gene BCL-2 as internal control. PCR was carried out in a 50 ml mixture containing genomic DNA and the following primers: 5 0 -TTCCT TACTGGTCCTCACATCTC, 5 0 -TCACCGGATCATGGCCAGCA for GSTT1, 5 0 -GAACTCCCTGAAAAGCTAAAGC, 5 0 -GTTGGGC TCAAATATACGGTGG for GSTM1 and 5 0 -GCAATTCCGCATT TAATTCATGG-3 0 , 5 0 -GAAACAGGCCACGTAAAGCAAC-3 0 for BCL-2. This results in a fragment of 480 bp for GSTT1, 219 bp for GSTM1 and 154 bp for BCL-2. Homozygous deletions correspond to absence of the GSTM1 and/or GTSTT1 band on a 2% ethidium bromide-stained agarose gel. 12 
Statistical analyses
The definition of complete remission (CR) followed the recommended criteria. 18 . OS was measured from entry into one of the prospective studies to death (failure) and alive at last follow-up (censored) as end points. Relapse-free survival (RFS) was measured from the date of documented CR to relapse (failure), death in CR (failure), and alive in CR at last follow-up (censored) as end points. In the survival analysis restricted to patients with a normal karyotype, patients undergoing allo-SCT were censored at the time of allo-SCT. Pairwise comparisons between GST genotypes and patient characteristics (covariates) were performed by Mann-Whitney test for continuous variables and by Fisher's exact test for categorical variables. Gray's k-sample test 19 was used for analysis of time to recovery of neutrophil and platelet counts and for competing risk analysis of RFS to account for failures due to relapse and failures due to toxicity, whereas analysis of variance models were calculated for associations between GST genotypes and toxicity data as number of transfusions and organ toxicity other than hematological (including WHO (World Health Organization) toxicity gradeX2 mucositis, pulmonary, cardiac and central nervous system toxicity and rate of febrile neutropenic episodes). The Kaplan-Meier method was used to estimate the distribution of RFS and OS. Survival distributions were compared using the logrank test, stratifying for the treatment groups (AML HD98-A and HD98B). A Cox model was used to identify prognostic variables. Patients with missing variables were excluded from the multivariate analysis. White blood cell (WBC) counts and lactate dehydrogenase (LDH) levels were analyzed as continuous variables after logarithmic transformation. To provide quantitative information on the relevance of results, 95% confidence intervals (95% CIs) of hazard ratios (HRs) were computed. Statistical analyses were performed with the software Stata 7.0 and the statistical software environment R, version 2.4.1 (R-Development-Core-Team, 2007).
Results
Genotype distribution and patient characteristics
We investigated the role of polymorphisms in genes encoding for drug-metabolizing enzymes in 354 newly diagnosed Caucasian patients with AML included in prospective clinical trials of the AMLSG. The distribution of the GSTP1 genotype was as follows: 41 patients (11.8%) were homozygous for the 105Val/105Val genotype, 142 patients (40.7%) were heterozygous (105Ile/105Val) and 166 patients (47.6%) were homozygous for 105Ile/105Ile GSTP1 genotype. The genotype distribution was in Hardy-Weinberg equilibrium (w 2 ¼ 1.54, P ¼ 0.22). Our observed allele frequency for the GSTP1 105Val allele was 0.32 (224/698).
The frequency of deletions in the GSTM1 gene (GSTM1*0) was 55.5% (196/353) and 17% (60/353) for the GSTT1 gene (GSTT1*0). Deletions of GSTM1 and GSTT1 (GSTT1*0/ GSTM1*0) occurred in 32/353 (9%) patients, whereas at least one deletion in GST genes was observed in 224/353 (63%) patients. The frequencies of the GSTP1 105Val allele and of GSTM1 and GSTT1 deletions were similar to other reports on healthy Caucasians. 17, 20, 21 We then looked for associations between demographic characteristics of the patients and GST genotypes ( Table 1) . Carriers of the GSTP1*105Val allele had lower WBC counts (10.8 vs 18.6 Â 10 9 per l, P ¼ 0.02), whereas AML patients with GSTM1*0 had increased LDH levels (462 vs 418 IU/l, P ¼ 0.05). FLT3-ITD were less common in patients with GSTT1*0 (6/60) than in patients with undeleted GSTT1 (70/287, P ¼ 0.015). Although a specific fluorescence in situ hybridization (FISH) analysis for the GST loci (GSTP1: chromosome 11q13; GSTT1: 22q11.2, GSTM1:1p13) has not been performed, we found no correlations between karyotypic aberrations involving chromosomes 11, 22 and 1 and GST polymorphisms.
GST genotypes and toxicity GST genotypes influence drug metabolism and may influence short-term adverse drug reactions induced by induction and consolidation chemotherapy, as myelosuppression, incidence of infections, nonhematological toxicity and the toxic death rate. The median time to neutrophil and platelet recovery measured from first day of chemotherapy was 15 (s.e. 0.39, n ¼ 832 cycles) and 12 (s.e. 0.44, n ¼ 855 cycles) days. In a stratified analysis for treatment/age group and chemotherapy cycle, the GSTP1*105 genotype was associated with a shorter neutrophil recovery and platelet recovery following induction therapy, wheras GSTT1 and GSTM1 deletions did not influence the speed of hematopoietic reconstitution. The median time for neutrophil and platelet recovery was 12 days after chemotherapy in homozygous carriers of the GSTP1*105Val allele, whereas it was 15 days both in carriers of the heterozygous and wild-type GSTP1*105 genotype (P ¼ 0.02 and 0.002, respectively; Figures  1a and b) . Carriers of the GSTP1*105 Val genotype also had a reduced need of RBC (n ¼ 6.6 units per cycle vs 7.3 and 8.2) and platelet transfusions (n ¼ 11.1 units per cycle vs 16.7 and 18.1 units; P ¼ 0.01 and 0.03, respectively), whereas GSTT1 and GSTM1 genotypes had no impact on transfusion frequencies.
The frequency of febrile neutropenic episodes, use of antibiotics and antifungals did not differ according to GST genotypes. Carriers of the GSTT1*0 genotype appeared to be at a higher risk for any WHO gradeX2 organ toxicity other than hematological (32.9 vs 21.6%, P ¼ 0.001). The incidence of the toxic death rate was 11.2% without differences between the various GST genotypes.
GST genotypes and response to induction therapy
Complete remission to induction therapy was achieved in 222/ 308 patients (72%). As treatment and response differed according to age group, all analyses were stratified according to this parameter (CR in group A, 81.4%; CR in group B, 53.7%, Po0.001). Using logistic regression analysis, GST genotypes did not predict for response to induction therapy (data not shown).
GST genotypes and survival
At a median follow-up of 46 months (range 0-221 months), the univariate analysis stratified for treatment/age group revealed that the GSTP1*105 genotype was significantly associated to RFS (P ¼ 0.03). Patients with the variant Val allele had a lower risk for RFS (adjusted HR, 0.7; 95% CI, 0.51-0.98; Table 2 ), whereas OS was not significantly influenced (P ¼ 0.15). Using a competing risk analysis to distinguish between failures due to relapse and failures due to toxicity, we found that the cumulative incidence of relapse was significantly lower for carriers of the variant GSTP1*105Val allele (P ¼ 0.05), whereas the cumulative incidence of toxic death did not differ according to the GSTP1*105Val allele (P ¼ 0.86; Figure 2 ). GSTT1 or GSTM1 genotypes in single or combined analyses showed no significant impact on RFS and OS.
We then included GST genotypes, LDH and WBC levels, cytogenetic risk and age groups, and FLT3-ITD status in a multivariable analysis. The Cox model for OS is based on the data of 323 patients with complete information for all parameters included, whereas the Cox model for relapse-free model is based on 236 patients. In these models, the GSTP1*105 genotype was a significant favorable variable for RFS and OS (P ¼ 0.003 and 0.03, respectively; Table 3 ).
We analyzed the impact of GST genotypes in patients with a normal karyotype. To avoid allogeneic stem cell transplantation (allo-SCT) as confounding factor, patients undergoing allo-SCT were censored at the time of allo-SCT (RFS: 109 patients, OS: 150 patients). In the univariate analysis accounting for competing risks, carriers of the GSTP1*105Val allele had a trend for a lower cumulative incidence of relapse (P ¼ 0.08), whereas there was no difference in the cumulative incidence rate of toxic death (P ¼ 0.96). In the multivariate analysis, the GSTP1*105Val allele was again an independent favorable prognostic factor for RFS, whereas it did not significantly influence OS (Table 4) . Specific patient-related factors have not been well identified, except for age and performance status. Genetic polymorphism of detoxification enzymes may explain differences in treatment outcome.
The metabolism of several drugs is affected by GST enzymes. Pharmacokinetic studies have identified the following anticancer drugs to be targets of the GSTP1 subfamily: doxorubicin, cisplatin, cyclophosphamide, melphalan, busulphan, chlorambucil, thiotepa, vincristine and etoposide. 4, [24] [25] [26] [27] The GSTP1*105Val allele is present in 30% of Caucasians and is associated with a decreased activity of the enzyme, when compared to the Ile allele, as measured by the conjugation of the substrate 1-chloro-2,4-dinitrobenzene and thiotepa. [28] [29] [30] In the present study we report for the first time that at a follow-up of almost 4 years the GSTP1*105Val allele is a favorable prognostic factor in patients with AML treated according to standard protocols and in particular those with a normal karyotype. The Cox model including also LDH level, cytogenetic risk and age group, and FLT3-ITD mutation status showed that the GSTP1 genotype was an independent prognostic marker for RFS in 236 patients and for OS in 323 patients.
In the same line, the GSTP1*105Val genotype has been associated with favorable prognosis in other malignancies, as breast and colon cancer and Hodgkin lymphoma. [31] [32] [33] We previously observed a higher probability of 5-year event-free survival for patients with Hodgkin lymphoma homozygous for the GSTP1*105Val allele in comparison to heterozygous patients and to patients homozygous for the GSTP1*105Ile allele. 33 A population-based case-control study performed in China, including 1034 patients with invasive breast cancer, treated with chemotherapy with or without radiotherapy and tamoxifen, reported that at a median follow-up of 5.3 years, women who were homozygous for the variant GSTP1*105Val allele had a 60% reduction in mortality risk compared to those Abbreviations: CI, confidence interval; OS, overall survival; RFS, relapse-free survival. Statistically significant differences are indicated in bold.
who were homozygous for the GSTP*105Ile allele. 34 Dasgupta et al. 35 observed a better survival for patients with multiple myeloma and the GSTP1*Val allele treated with conventional chemotherapy, whereas they did not observe any difference in outcome in those treated with high-dose therapy.
It is hypothesized that the improved outcome in cancer patients with the GSTP1*Val allele is due to a reduced detoxification of chemotherapeutic agents and thus an intensified cytotoxic effect. In this line one might also expect an increased hematologic toxicity after chemotherapy. There are only few data reported on differences in myelotoxicity by GSTP1 genotypes. In a group of 102 Chinese patients with systemic lupus erythematosus, the GSTP1*105Val allele significantly increased the risks of short-term side effects as myelosuppression of pulsed high-dose cyclophosphamide (CTX) therapy. 36 In a group of 46 patients with bladder cancer, individuals with the GSTP1*Val allele showed a higher myelotoxicity after the chemotherapy regimen M-VAC. 37 Our finding of a reduced hematoxicity after chemotherapy in AML patients with the GSTP1*105Val allele, based on the analysis of 832 treatment cycles from 307 patients, appears to be in contrast with these data. One hypothesis could be that different from solid tumors, residual hematopoiesis is severely impaired in AML at diagnosis, and an improved eradication of leukemic cells after chemotherapy might result in a more rapid restoration of normal hematopoiesis. On the other hand, one has to bear in mind that GSTP1 is not only involved in detoxification of cytotoxic agents, but also has multiple additional functions, in particular affecting cell proliferation and apoptosis, by interaction with JNK signaling. 6 Under oxidative stress or treatment with DNAdamaging agents, GSTP1 oligomerizes and dissociates from JNK, which then becomes phosphorylated leading to increased apoptosis. 6, 8, 9 Interestingly, GSTP1-deficient mice show an enhanced myeloproliferation with higher levels of circulating WBCs, and growth factors were more effective in stimulating hematopoiesis in these mice, probably due to an increased activity of JNK and STATs. 38 Moreover, JNK activity appears to be an important regulator of proliferation in immature erythroid cells. 39 A significant myelostimulant activity in human bone marrow cell cultures was observed in vitro after treatment with TLK199, a glutathione analog which selectively binds and inhibits GSTP1. 40 Studies in rodents have shown that treatment with TLK199 increased the levels of circulating WBCs, accelerated the recovery of circulating neutrophils in fluorouracil-induced neutropenia and enhanced granulocyte-colony stimulating factor serum levels. 41 In the same line, in phase I and II clinical trials treatment with oral or i.v. TLK199 of patients with refractory myelodyspastic syndromes (MDS), resulted in significant hematological improvement of neutrophil, erythrocyte and/or platelet counts. 42, 43 Taken together, these results fit well together with the reduced hematotoxicity observed in our study.
On the basis of the results of our current study, including patients from a multicenter prospective clinical trial, we cannot confirm the prognostic impact of GSTT1 and/or GSTM1 deletions, observed in our previous study in patients with a normal karyotype from a single center. 12 These conflicting results indicate that gene polymorphisms may exert only small effects and many studies on gene polymorphisms are underpowered and false-positive and false-negative results may occur, especially at short follow-up times. In this line, GST deletions were associated to a lower probability of disease-free survival in 306 children with AML. 10 Children with GSTT1*0 genotype had increase treatment-related mortality and reduced survival, especially when receiving intensively timed therapy. In line with these results, we observed an association of an increase in extrahematological toxicity with the GSTT1*0 genotype, although this did not result in an increase in the toxic death rate. Davies et al. 44 also reported no influence of GSTT1 and GSTM1 genotypes on the survival of a large group of 710 children with acute lymphoblastic leukemia, treated by risk-adapted Children's Cancer Group protocols.
In conclusion, we demonstrate in a large, prospectively collected and homogenously treated AML patient group that the GSTP1*105 genotype is a prognostic factor, adding independent information to the routine laboratory parameters and cytogenetic and molecular alterations of the tumor cells.
